RxDoctor Payments Data

Christina Joslin, DO

Family Medicine · Oxford, MINPI 1457410987

Payments from drug & device makers

$5,891in general payments, 2019–2025

Across 378 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$945
  • Pfizer$587
  • Lilly USA, LLC$459
  • Astellas Pharma US Inc$417
  • Amgen$335
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,79298%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,891 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$81,890
Medicare patients
134
Services billed
1,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$132,324
JardianceEmpagliflozin51$69,945
MounjaroTirzepatide39$50,686
Teriparatide14$47,997
EliquisApixaban47$45,995
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$36,591
TrulicityDulaglutide11$22,533
Repatha SureclickEvolocumab16$13,023
ArexvyRsvpref3 Antigen/As01e/Pf15$4,737
AbrysvoRsv Vacc, Pref A And Pref B/Pf14$4,500
Atorvastatin Calcium321$4,049
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,359
Levothyroxine Sodium280$3,126
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,106
Metoprolol Succinate140$2,553

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$945$132,32485 claims
Lilly USA, LLCMounjaro, Trulicity$459$73,21950 claims
Boehringer IngelheimJardiance$15$69,94551 claims
PfizerEliquis, Abrysvo$587$50,49561 claims
Alvogen IncTeriparatide$65$47,99714 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$214$44,43461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Oxford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →